Langerin Inhibitors
Langerin inhibitors are a class of chemical compounds designed to specifically target and block the activity of the Langerin protein, which is a C-type lectin receptor expressed primarily on Langerhans cells, a type of dendritic cell found in the skin and mucosa. Langerin plays a crucial role in the recognition and internalization of glycosylated antigens by binding to specific sugar moieties, such as mannose and N-acetylglucosamine. This interaction allows Langerin to mediate the capture and processing of various molecules, facilitating antigen presentation. Langerin also facilitates the formation of Birbeck granules, which are unique cellular structures that assist in antigen processing. By inhibiting Langerin, researchers can explore its role in cellular processes, particularly its involvement in antigen recognition, internalization, and intracellular trafficking.
The chemical structure of Langerin inhibitors typically includes elements that disrupt the interaction between Langerin and its glycosylated ligands. These inhibitors may function by binding directly to the carbohydrate recognition domain (CRD) of Langerin, blocking its ability to interact with sugars on the surface of potential antigens. Alternatively, some inhibitors may prevent the oligomerization of Langerin, which is necessary for its proper functioning in cellular signaling and antigen processing. The inhibition of Langerin allows researchers to study its role in immune cell behavior, particularly in the context of cellular communication and the handling of foreign molecules. Through the use of these inhibitors, the specific biochemical pathways influenced by Langerin can be dissected, offering deeper insights into how this protein contributes to the broader immune system and cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Manumycin A inhibits Ras farnesyltransferase, impacting the Ras signaling pathway. Langerin, involved in antigen presentation, may be indirectly modulated as Ras signaling influences dendritic cell maturation and function. Manumycin A can alter Langerin-associated processes related to antigen presentation and immune response. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Lovastatin, a HMG-CoA reductase inhibitor, influences the mevalonate pathway. Langerin expression is affected by mevalonate pathway intermediates. Lovastatin can modulate Langerin expression levels, potentially impacting Langerin-mediated functions in antigen presentation and immune responses. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW9662 is a PPARγ antagonist, impacting the PPARγ signaling pathway. Langerin expression can be influenced by PPARγ activation. GW9662 can modulate Langerin-associated processes, potentially affecting Langerin-mediated antigen presentation and immune responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that influences the p38 MAPK signaling pathway. Langerin expression and function are linked to MAPK signaling. SB203580 can alter Langerin-associated processes related to dendritic cell maturation and immune responses. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB202190, another p38 MAPK inhibitor, influences the p38 MAPK signaling pathway similarly to SB203580. Langerin, as a dendritic cell marker, may be indirectly modulated by SB202190, affecting dendritic cell maturation and immune responses. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Fluorouracil, an antimetabolite, interferes with DNA and RNA synthesis. Langerin expression may be affected as it is linked to cellular proliferation and differentiation. Fluorouracil can influence Langerin-associated processes by altering cellular pathways related to proliferation, potentially impacting Langerin-mediated antigen presentation and immune responses. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3-kinase inhibitor, influencing the PI3-kinase signaling pathway. Langerin expression can be modulated by PI3-kinase activity. Wortmannin can alter Langerin-associated processes, potentially affecting Langerin-mediated antigen presentation and immune responses. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, another PI3-kinase inhibitor, influences the PI3-kinase signaling pathway similarly to Wortmannin. Langerin, as a dendritic cell marker, may be indirectly modulated by LY294002, affecting dendritic cell maturation and immune responses. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor, impacting various signaling pathways. Langerin expression may be influenced by tyrosine kinase activity. Imatinib can modulate Langerin-associated processes, potentially affecting Langerin-mediated antigen presentation and immune responses. | ||||||
BAY 61-3606 | sc-507485 | 2 mg | $345.00 | 1 | ||
BAY 61-3606 is a Syk inhibitor that influences the Syk signaling pathway. Langerin expression may be affected, as Syk is involved in immune cell activation. BAY 61-3606 can modulate Langerin-associated processes, potentially affecting Langerin-mediated antigen presentation and immune responses. | ||||||